Maysa Abu-Khalaf

TitleProfessor
InstitutionThomas Jefferson University
DepartmentMedical Oncology
Address925 Chestnut Street
Philadelphia PA 19107
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Wang C, Mu Z, Ye Z, Zhang Z, Abu-Khalaf MM, Silver DP, Palazzo JP, Jagannathan G, Fellin FM, Bhattacharya S, Jaslow RJ, Tsangaris TN, Berger A, Neupane M, Cescon TP, Lopez A, Yao K, Chong W, Lu B, Myers RE, Hou L, Wei Q, Li B, Cristofanilli M, Yang H. Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. Breast Cancer Res Treat. 2020 May 04. PMID: 32367460.
      Citations:    
    2. Abu-Khalaf MM, Safonov A, Stratton J, Wang S, Hatzis C, Park E, Pusztai L, Gross CP, Russell R. Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy. Breast Cancer Res Treat. 2019 Apr 24. PMID: 31020471.
      Citations:    
    3. Garrido-Laguna I, Krop I, Burris HA, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, Lakshminarayanan M, Holland JS, Baffa R, Hong DS. First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer. 2019 Jan 24. PMID: 30680712.
      Citations:    
    4. Ye Z, Wang C, Wan S, Mu Z, Zhang Z, Abu-Khalaf MM, Fellin FM, Silver DP, Neupane M, Jaslow RJ, Bhattacharya S, Tsangaris TN, Chervoneva I, Berger A, Austin L, Palazzo JP, Myers RE, Pancholy N, Toorkey D, Yao K, Krall M, Li X, Chen X, Fu X, Xing J, Hou L, Wei Q, Li B, Cristofanilli M, Yang H. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. Eur J Cancer. 2019 Jan; 106:133-143. PMID: 30528798.
      Citations:    
    5. Abu-Khalaf M, Muralikrishnan S, Hatzis C, Canchi D, Yu JB, Chiang V. Breast cancer patients with brain metastasis undergoing GKRS. Breast Cancer. 2018 Sep 04. PMID: 30182250.
      Citations:    
    6. Rodon J, Pérez-Fidalgo A, Krop IE, Burris H, Guerrero-Zotano A, Britten CD, Becerra C, Schellens J, Richards DA, Schuler M, Abu-Khalaf M, Johnson FM, Ranson M, Edenfield J, Silva AP, Hackl W, Quadt C, Demanse D, Duval V, Baselga J. Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. Cancer Chemother Pharmacol. 2018 Jun 07. PMID: 29882016.
      Citations:    
    7. Lynce F, Saleh M, Shajahan-Haq A, Gallagher C, Dilawari A, Hahn O, Abu-Khalaf M, Cai L, Pohlmann P, Mohebtash M, Kamugisha L, Isaacs C. PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. Contemp Clin Trials Commun. 2018 Jun; 10:190-192. PMID: 30009277.
      Citations:    
    8. Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Burrello T, Abu-Khalaf M, Sabbath K, Sanft T, Brandt DS, Hofstatter EW, Hatzis C, DiGiovanna MP, Pusztai L. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer. Breast Cancer Res Treat. 2018 Jun; 169(2):333-340. PMID: 29396664.
      Citations:    
    9. Mougalian SS, Epstein LN, Jhaveri AP, Han G, Abu-Khalaf M, Hofstatter EW, DiGiovanna MP, Silber ALM, Adelson K, Pusztai L, Gross CP. Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer. JCO Clin Cancer Inform. 2017 11; 1:1-10. PMID: 30657377.
      Citations:    
    10. Dzimitrowicz H, Mougalian S, Storms S, Hurd S, Chagpar AB, Killelea BK, Horowitz NR, Lannin DR, Harigopal M, Hofstatter E, DiGiovanna MP, Adelson KB, Silber A, Abu-Khalaf M, Chung G, Zaheer W, Abdelghany O, Hatzis C, Pusztai L, Sanft TB. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making. J Oncol Pract. 2017 Dec; 13(12):e1012-e1020. PMID: 29048991.
      Citations:    
    11. Fratamico RS, Strickland KS, Uppal G, Abu-Khalaf M. A Case of Carcinocythemia: De Novo Hormone Receptor-positive Metastatic Breast Cancer Presenting With Circulating Tumor Cells Mimicking an Acute Leukemia. Clin Breast Cancer. 2018 Jun; 18(3):e295-e298. PMID: 28735676.
      Citations:    
    12. Davis BA, Aminawung JA, Abu-Khalaf MM, Evans SB, Su K, Mehta R, Wang SY, Gross CP. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study. J Natl Compr Canc Netw. 2017 Mar; 15(3):346-354. PMID: 28275035.
      Citations:    
    13. Wang C, Mu Z, Chervoneva I, Austin L, Ye Z, Rossi G, Palazzo JP, Sun C, Abu-Khalaf M, Myers RE, Zhu Z, Ba Y, Li B, Hou L, Cristofanilli M, Yang H. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Breast Cancer Res Treat. 2017 Jan; 161(1):83-94. PMID: 27771841.
      Citations:    
    14. Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. Proc Natl Acad Sci U S A. 2016 Oct 25; 113(43):12238-12243. PMID: 27791010.
      Citations:    
    15. Muralikrishnan S, Hatzis C, Katz A, Santin A, Schwartz PE, Abu-Khalaf MM. Chemotherapy for Elderly Ovarian Cancer Patients. Gynecol Obstet (Sunnyvale). 2016 Aug; 6(8). PMID: 27695647.
      Citations:    
    16. Patel JM, Knopf J, Reiner E, Bossuyt V, Epstein L, DiGiovanna M, Chung G, Silber A, Sanft T, Hofstatter E, Mougalian S, Abu-Khalaf M, Platt J, Shi W, Gershkovich P, Hatzis C, Pusztai L. Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools. Oncotarget. 2016 Apr 19; 7(16):22064-76. PMID: 26980737.
      Citations:    
    17. Yushak ML, Han G, Bouberhan S, Epstein L, DiGiovanna MP, Mougalian SS, Sanft TB, Abu-Khalaf MM, Chung GG, Stein SM, Goldberg SB, Pusztai L, Hofstatter EW. Patient preferences regarding incidental genomic findings discovered during tumor profiling. Cancer. 2016 May 15; 122(10):1588-97. PMID: 26970385.
      Citations:    
    18. Pusztai L, Karn T, Safonov A, Abu-Khalaf MM, Bianchini G. New Strategies in Breast Cancer: Immunotherapy. Clin Cancer Res. 2016 May 1; 22(9):2105-10. PMID: 26867935.
      Citations:    
    19. Varadan V, Gilmore H, Miskimen KL, Tuck D, Parsai S, Awadallah A, Krop IE, Winer EP, Bossuyt V, Somlo G, Abu-Khalaf MM, Fenton MA, Sikov W, Harris LN. Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer. Clin Cancer Res. 2016 Jul 1; 22(13):3249-59. PMID: 26842237.
      Citations:    
    20. Su KW, Hall J, Soulos PR, Abu-Khalaf MM, Evans SB, Mougalian SS, Rutter CE, Davidoff AJ, Gross CP. Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-2011. J Geriatr Oncol. 2016 Jan; 7(1):15-23. PMID: 26704661.
      Citations:    
    21. Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer. Breast Cancer Res Treat. 2015 Dec; 154(3):533-41. PMID: 26578401.
      Citations:    
    22. Rutter CE, Yao X, Mancini BR, Aminawung JA, Chagpar AB, Saglam O, Hofstatter EW, Abu-Khalaf M, Gross CP, Evans SB. Influence of a 21-Gene Recurrence Score Assay on Chemotherapy Delivery in Breast Cancer. Clin Breast Cancer. 2016 Feb; 16(1):59-62. PMID: 26483315.
      Citations:    
    23. Varadan V, Kamalakaran S, Gilmore H, Banerjee N, Janevski A, Miskimen KL, Williams N, Basavanhalli A, Madabhushi A, Lezon-Geyda K, Bossuyt V, Lannin DR, Abu-Khalaf M, Sikov W, Dimitrova N, Harris LN. Brief-exposure to preoperative bevacizumab reveals a TGF-ß signature predictive of response in HER2-negative breast cancers. Int J Cancer. 2016 Feb 1; 138(3):747-57. PMID: 26284485.
      Citations:    
    24. Hatzis C, Symmans WF, Zhang Y, Gould RE, Moulder SL, Hunt KK, Abu-Khalaf M, Hofstatter EW, Lannin D, Chagpar AB, Pusztai L. Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer. Clin Cancer Res. 2016 Jan 1; 22(1):26-33. PMID: 26286912.
      Citations:    
    25. Oprea AD, Russell RR, Russell KS, Abu-Khalaf M. Chemotherapy Agents With Known Cardiovascular Side Effects and Their Anesthetic Implications. J Cardiothorac Vasc Anesth. 2015 Jun 12. PMID: 26952170.
      Citations:    
    26. Mougalian SS, Soulos PR, Killelea BK, Lannin DR, Abu-Khalaf MM, DiGiovanna MP, Sanft TB, Pusztai L, Gross CP, Chagpar AB. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. 2015 Aug 1; 121(15):2544-52. PMID: 25902916.
      Citations:    
    27. Bulloch KJ, Irwin ML, Chagpar AB, Pusztai L, Killelea BK, Horowitz NR, Hofstatter EW, Abu-Khalaf MM, DiGiovanna M, Chung GG, Sanft TB. Systematic approach to providing breast cancer survivors with survivorship care plans: a feasibility study. J Oncol Pract. 2015 Mar; 11(2):e170-6. PMID: 25784577.
      Citations:    
    28. Acevedo-Gadea C, Hatzis C, Chung G, Fishbach N, Lezon-Geyda K, Zelterman D, DiGiovanna MP, Harris L, Abu-Khalaf MM. Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy. Breast Cancer Res Treat. 2015 Feb; 150(1):157-67. PMID: 25687356.
      Citations:    
    29. Abu-Khalaf MM, Baumgart MA, Gettinger SN, Doddamane I, Tuck DP, Hou S, Chen N, Sullivan C, Lezon-Geyda K, Zelterman D, Hatzis C, Deshpande H, Digiovanna MP, Azodi M, Schwartz PE, Harris LN. Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors. Cancer. 2015 Jun 1; 121(11):1817-26. PMID: 25649370.
      Citations:    
    30. Fenn KM, Evans SB, McCorkle R, DiGiovanna MP, Pusztai L, Sanft T, Hofstatter EW, Killelea BK, Knobf MT, Lannin DR, Abu-Khalaf M, Horowitz NR, Chagpar AB. Impact of financial burden of cancer on survivors' quality of life. J Oncol Pract. 2014 Sep; 10(5):332-8. PMID: 24865220.
      Citations:    
    31. Cheng H, Bai Y, Sikov W, Sinclair N, Bossuyt V, Abu-Khalaf MM, Harris LN, Rimm DL. Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab. BMC Cancer. 2014 May 08; 14:326. PMID: 24885187.
      Citations:    
    32. Acevedo-Gadea C, Santin AD, Higgins SA, Urva S, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Abu-Khalaf MM. Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer. Int J Gynecol Cancer. 2014 Mar; 24(3):528-33. PMID: 24557436.
      Citations:    
    33. Chang B, Sokhn J, James E, Abu-Khalaf M. Prolonged progression-free survival in a patient with triple-negative breast cancer metastatic to the liver after chemotherapy and local radiation therapy. Clin Breast Cancer. 2014 Apr; 14(2):e61-4. PMID: 24373644.
      Citations:    
    34. Gross CP, Long JB, Ross JS, Abu-Khalaf MM, Wang R, Killelea BK, Gold HT, Chagpar AB, Ma X. The cost of breast cancer screening in the Medicare population. JAMA Intern Med. 2013 Feb 11; 173(3):220-6. PMID: 23303200.
      Citations:    
    35. Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A. 2013 Feb 19; 110(8):2916-21. PMID: 23359684.
      Citations:    
    36. Alsamarai S, Abu-Khalaf MM, Harris LN. DTCs/CTCs in breast cancer: five decades later. Recent Results Cancer Res. 2012; 195:217-25. PMID: 22527509.
      Citations:    
    37. Abu-Khalaf MM, Bader F. Cancer therapy related cardiotoxicity. Curr Cardiol Rev. 2011 Nov; 7(4):213. PMID: 22758621.
      Citations:    
    38. Gunturu KS, Abu-Khalaf M, Saif MW. Hepatic failure and hepatorenal syndrome secondary to erlotinib: a possible etiology of complications in a patient with pancreatic cancer. JOP. 2010; 11(5):484-5. PMID: 20818124.
      Citations:    
    39. Cocco E, Casagrande F, Bellone S, Richter CE, Bellone M, Todeschini P, Holmberg JC, Fu HH, Montagna MK, Mor G, Schwartz PE, Arin-Silasi D, Azoudi M, Rutherford TJ, Abu-Khalaf M, Pecorelli S, Santin AD. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC Cancer. 2010 Jul 02; 10:349. PMID: 20598131.
      Citations:    
    40. El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). Mol Cancer Ther. 2010 Jan; 9(1):57-66. PMID: 20053761.
      Citations:    
    41. Hazin R, Abuzetun JY, Daoud YJ, Abu-Khalaf MM. Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients. Curr Opin Ophthalmol. 2009 Jul; 20(4):308-17. PMID: 19491683.
      Citations:    
    42. Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, Hayes DF, Friedman P, Ellis M, Dressler L. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol. 2009 Jul 20; 27(21):3430-6. PMID: 19470942.
      Citations:    
    43. Abu-Khalaf MM, Harris L. Anthracycline-induced cardiotoxicity: risk assessment and management. Oncology (Williston Park). 2009 Mar; 23(3):239, 244, 252. PMID: 19418825.
      Citations:    
    44. Christy CJ, Thorsteinsson D, Grube BJ, Black D, Abu-Khalaf M, Chung GG, DiGiovanna MP, Miller K, Higgins SA, Weidhaas J, Harris L, Tavassoli FA, Lannin DR. Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter. Ann Surg Oncol. 2009 Mar; 16(3):697-702. PMID: 19132447.
      Citations:    
    45. Abu-Khalaf MM, Harris L. The prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer. Breast Cancer Res Treat. 2009 Apr; 114(3):513-5. PMID: 18677560.
      Citations:    
    46. Grube BJ, Christy CJ, Black D, Martel M, Harris L, Weidhaas J, Digiovanna MP, Chung G, Abu-Khalaf MM, Miller KD, Higgins SA, Philpotts L, Tavassoli FA, Lannin DR. Breast sentinel lymph node dissection before preoperative chemotherapy. Arch Surg. 2008 Jul; 143(7):692-9; discussion 699-700. PMID: 18645113.
      Citations:    
    47. Abu-Khalaf MM, Juneja V, Chung GG, DiGiovanna MP, Sipples R, McGurk M, Zelterman D, Haffty B, Reiss M, Wackers FJ, Lee FA, Burtness BA. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer. Breast Cancer Res Treat. 2007 Sep; 104(3):341-9. PMID: 17051423.
      Citations:    
    48. Abu-Khalaf MM, Windsor S, Ebisu K, Salikooti S, Ananthanarayanan G, Chung GG, DiGiovanna MP, Haffty BG, Abrams M, Farber LR, Hsu AD, Reiss M, Zelterman D, Burtness BA. Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer. Oncology. 2005; 69(5):372-83. PMID: 16319508.
      Citations:    
    Abu-Khalaf's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (183)
    Explore
    _
    Co-Authors (14)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _